person:james raftery

RFC 7676 : IPv6 Support for Generic Routing Encapsulation (GRE)

Le protocole #GRE est le plus simple mécanisme de #tunnel_informatique normalisé. Il est mis en œuvre sur d’innombrables systèmes, et très largement répandu. Pour reprendre la formule de James Raftery, GRE est « The AK-47 of guerrilla networking. Cheap, simple, gets all sorts of dirty jobs done. ». Il ne fonctionnait traditionnellement qu’avec IPv4 mais bien des mises en œuvre de GRE avaient été adaptées à #IPv6 depuis longtemps. Ce #RFC décrit cette adaptation.

▻http://www.bortzmeyer.org/7676.html

Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding | The BMJ
▻http://www.bmj.com/content/348/bmj.g1445

Deborah Cohen and James Raftery ask why one of the first drugs to be developed by a partnership between a charity and a drug company also ended up being one of the world’s most expensive drugs. Why didn’t such philanthropy lead to greater patient access?

In early 2012, the first drug targeting the underlying cause of cystic fibrosis was approved in Europe and the United States. Ivacaftor’s (Kalydeco) arrival was greeted with a flurry of excitement.

Billed as a “game changer” by industry pundits and “a profoundly exciting development” by National Institutes of Health director, Francis Collins, ivacaftor soon became one of the world’s most expensive medicines—its mode of action considered as exciting as its unique funding model. (...)

New model of funding

Ivacaftor is the first drug developed through “venture philanthropy”—a partnership between a charity and a drug company. It’s an emerging trend in drug development, particularly for rare conditions, whereby a non-profit organisation helps to finance the development of a treatment in return for a share in profits.

#pharma #prize #recherche #santé